Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedApr 28, 2026
DataAggregated Company Financials
Companies61
  • 7D-8.1%
  • 3M-22.6%
  • 1Y4.3%
  • YTD-19.5%

Over the last 7 days, the Life Sciences industry has dropped 8.1%, driven by Thermo Fisher Scientific declining 11%. On the other hand West Pharmaceutical Services is actually up 8.7%. In the past year, the industry has gained 4.3%. Earnings are forecast to grow by 16% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 28 Apr 2026US$546.1bUS$149.1bUS$14.4b30.9x38x3.7x
Thu, 26 Mar 2026US$553.6bUS$147.8bUS$14.0b36x39.4x3.7x
Sat, 21 Feb 2026US$597.1bUS$147.7bUS$13.8b33.8x43.2x4x
Mon, 19 Jan 2026US$693.3bUS$145.8bUS$12.4b36.8x56.1x4.8x
Wed, 17 Dec 2025US$660.5bUS$145.8bUS$12.5b34.7x52.9x4.5x
Fri, 14 Nov 2025US$657.5bUS$145.7bUS$12.2b34.8x54.1x4.5x
Sun, 12 Oct 2025US$609.0bUS$144.3bUS$14.6b31.7x41.8x4.2x
Tue, 09 Sep 2025US$582.1bUS$144.3bUS$14.6b29.8x40x4x
Thu, 07 Aug 2025US$555.5bUS$144.1bUS$13.0b28.2x42.7x3.9x
Sat, 05 Jul 2025US$548.4bUS$142.9bUS$9.1b36.4x60.1x3.8x
Mon, 02 Jun 2025US$504.6bUS$142.9bUS$9.2b32.4x54.6x3.5x
Wed, 30 Apr 2025US$518.0bUS$142.5bUS$10.0b37.8x51.8x3.6x
Fri, 28 Mar 2025US$589.1bUS$143.0bUS$9.9b38.5x59.5x4.1x
Sun, 23 Feb 2025US$619.6bUS$143.3bUS$9.7b38.8x63.8x4.3x
Tue, 21 Jan 2025US$681.4bUS$142.4bUS$10.2b43.8x66.8x4.8x
Thu, 19 Dec 2024US$664.1bUS$142.4bUS$10.2b43.3x65x4.7x
Sat, 16 Nov 2024US$667.9bUS$142.4bUS$10.4b41.8x64.4x4.7x
Mon, 14 Oct 2024US$731.7bUS$141.8bUS$8.5b37.7x86.1x5.2x
Wed, 11 Sep 2024US$739.9bUS$141.8bUS$8.5b38.3x87.1x5.2x
Fri, 09 Aug 2024US$714.4bUS$141.6bUS$8.4b38.7x84.7x5x
Sun, 07 Jul 2024US$664.6bUS$141.3bUS$12.2b38.8x54.6x4.7x
Tue, 04 Jun 2024US$702.1bUS$141.3bUS$12.4b38.5x56.5x5x
Thu, 02 May 2024US$706.3bUS$141.5bUS$12.7b39.4x55.8x5x
Sat, 30 Mar 2024US$744.3bUS$142.1bUS$12.8b44x58.1x5.2x
Mon, 26 Feb 2024US$729.9bUS$142.1bUS$12.4b43.7x58.9x5.1x
Wed, 24 Jan 2024US$697.0bUS$153.8bUS$14.2b35.8x49.2x4.5x
Fri, 22 Dec 2023US$687.0bUS$153.8bUS$14.2b37.5x48.2x4.5x
Sun, 19 Nov 2023US$614.3bUS$153.9bUS$13.9b33.5x44.2x4x
Tue, 17 Oct 2023US$632.5bUS$154.6bUS$11.2b33.2x56.5x4.1x
Thu, 14 Sep 2023US$692.7bUS$154.6bUS$11.2b33.1x61.8x4.5x
Sat, 12 Aug 2023US$725.3bUS$154.7bUS$11.5b32x63.1x4.7x
Mon, 10 Jul 2023US$685.3bUS$152.4bUS$12.5b29.6x54.8x4.5x
Wed, 07 Jun 2023US$682.6bUS$152.4bUS$12.5b29.1x54.6x4.5x
Fri, 05 May 2023US$699.3bUS$152.7bUS$9.6b28.3x72.5x4.6x
Price to Earnings Ratio

72.5x


Total Market Cap: US$699.3bTotal Earnings: US$9.6bTotal Revenue: US$152.7bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 57x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 38.0x which is lower than its 3-year average PE of 57.0x.
  • The 3-year average PS ratio of 4.5x is higher than the industry's current PS ratio of 3.7x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 14% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.72%
Healthcare-2.64%
Life Sciences-8.11%
Clinical Research and Equipment-8.11%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
WST West Pharmaceutical ServicesUS$302.208.7%
+US$1.3b		39.8%PE39.3x
ALMR Alamar BiosciencesUS$26.6921.3%
+US$319.9m		n/aPS24.5x
STVN Stevanato GroupUS$16.182.0%
+US$87.4m		-25.0%PE26.9x
ABCL AbCellera BiologicsUS$4.166.4%
+US$75.8m		60.6%PS16.8x
FTRE Fortrea HoldingsUS$10.601.5%
+US$15.0m		74.3%PS0.4x

Latest News

MRVI
US$3.68
Maravai LifeSciences Holdings
7D
1.9%
1Y
83.1%
MTD
US$1,274.70
Mettler-Toledo International
7D
-3.8%
1Y
20.1%

MTD: Ongoing Buybacks And 2026 Sales Outlook Will Drive Future Upside

Analysts have reduced their price target for Mettler-Toledo International by about $10. This change reflects slightly updated assumptions for fair value, discount rate, revenue growth and future P/E, while projected profit margins are expected to remain broadly similar.
MEDP
US$421.37
Medpace Holdings
7D
-20.3%
1Y
41.3%

Medpace Holdings, Inc. Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

Apr 26
Medpace Holdings, Inc. Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
WST
US$302.20
West Pharmaceutical Services
7D
8.7%
1Y
39.8%
A
US$115.62
Agilent Technologies
7D
-4.4%
1Y
8.2%

A: New Diagnostic Approvals And Buybacks Will Support Long Term Upside

Analysts have trimmed their price target on Agilent Technologies by about $1 to $160.69, reflecting slightly adjusted views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Supreme Court of the United States denied Agilent Technologies' petition related to two CRISPR guide RNA patents, leaving in place prior rulings that found all claims of the patents unpatentable.
STVN
US$16.18
Stevanato Group
7D
2.0%
1Y
-25.0%
TMO
US$468.04
Thermo Fisher Scientific
7D
-11.0%
1Y
11.1%
TKNO
US$3.14
Alpha Teknova
7D
7.9%
1Y
-53.2%
DHR
US$180.62
Danaher
7D
-7.6%
1Y
-7.8%

Danaher Q1 2026 Earnings Update

Apr 22
ICLR
US$103.21
ICON
7D
-11.9%
1Y
-28.8%

ICLR: Oncology And Site Network Expansion Will Offset Accounting Overhang

ICON's updated analyst price target has shifted from about $142.86 to roughly $132.08 as analysts factor in lower modeled revenue growth, a slightly different discount rate, and a reduced future P/E, partly offset by a modestly higher profit margin outlook and mixed reactions to the recent accounting investigation and subsequent ratings changes. Analyst Commentary Recent research on ICON reflects a wide range of opinions as firms reassess the stock following the internal accounting investigation, reduced price targets, and updates to sector models in life science tools, diagnostics, and contract research organizations.
FTRE
US$10.60
Fortrea Holdings
7D
1.5%
1Y
74.3%

FTRE: Conservative 2026 Guidance And AI Tools May Support Re Rating

The analyst price target for Fortrea has been reset from about $22.59 to $16.00 as analysts factor in updated fair value assumptions, slightly lower revenue growth and profit margin inputs, and a lower future P/E multiple, while also incorporating recent Street research that adjusts targets across firms in response to evolving views on the company's fundamentals and guidance. Analyst Commentary Recent Street research on Fortrea shows a mix of trimmed price targets and selective upgrades, as analysts recalibrate their models around updated guidance and sector views.
ABCL
US$4.16
AbCellera Biologics
7D
6.4%
1Y
60.6%
ALMR
US$26.69
Alamar Biosciences
7D
21.3%
1Y
n/a

Alamar Biosciences: Looking For An Early Detection

Apr 19
WAT
US$299.79
Waters
7D
-10.7%
1Y
-11.8%

WAT: Reorganization And Product Pipeline Will Likely Keep Upside In Check

Analysts have kept their price target for Waters steady at $330.00, citing updated assumptions for slightly higher revenue growth, a wider profit margin, and a higher future P/E multiple as the key drivers behind the unchanged fair value view. What's in the News Launched the Waters omniDAWN Multi-Angle Light Scattering Photometer for UHPLC and UPLC workflows, targeting absolute molar mass and size measurements for complex analytes such as protein aggregates, viral vectors, lipid nanoparticles, and advanced materials.
IQV
US$163.84
IQVIA Holdings
7D
-7.3%
1Y
9.1%

IQV: Data And Clinical Trial Scale Will Support Earnings Reacceleration

The analyst price target for IQVIA Holdings has been reset from $250.00 to $231.60 as analysts factor in updated models after recent Q4 results, AI related uncertainties, and broader sector target cuts, while still highlighting the company’s data and clinical trial capabilities in several upgraded ratings. Analyst Commentary Recent research updates on IQVIA show a mix of optimism around the company’s data assets and clinical trial exposure, alongside caution as models are reset after Q4 results and AI related questions.
RPID
US$2.36
Rapid Micro Biosystems
7D
4.9%
1Y
0.9%